Due to The Risk of Cancer FDA Expands Blood Pressure Drug Recall

Due to The Risk of Cancer FDA Expands Blood Pressure Drug Recall

The Food and Drug Administration is once more expanding its recall of widely prescribed blood pressure drugs because of contamination with a cancer-causing chemical.

The announcement made on Monday targets a further five lots of the generic drug losartan produced by Torrent Pharmaceuticals Limited company. The lots combine losartan potassium tablets and losartan potassium/hydrochlorothiazide tablets.

The recalled lots contain hint amounts of N-methylnitrosobutyric acid, or NMBA, which has been linked to cancer.

That makes the fifth time in the year 2019 that Torrent Pharmaceuticals has grown its voluntary recall of losartan. The recall was first stated in January month.

Losartan is known for generic angiotensin II receptor blocker or also called as ARB, and is used to treat hypertension as well as heart failure. Over the past year, scores of batches of generic ARBs have been withdrawn from the market because of the presence of chemical contaminants referred to as nitrosamines, which have been linked to risk of certain kinds of cancer.

About the author

Kellie Jasper

Kellie heads the health column. She is a woman with very positive vibes and organizational skills. She is a professional in diet and nutrition, and hence her articles are mainly about healthy recipes. She is an excellent chef and loves to make food which is healthy but delicious. She is always very focused on her work, and when not found in her desk she can be found in the cafeteria having her favorite chamomile tea. It has been 5 years since she is working here.